Trials / Terminated
TerminatedNCT04999605
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Phase Ib/II Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody (AK112) Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Akeso · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112 low dose | AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor |
| DRUG | AK112 medium dose | AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor |
| DRUG | AK112 high dose | AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor |
Timeline
- Start date
- 2021-06-24
- Primary completion
- 2022-06-10
- Completion
- 2022-06-10
- First posted
- 2021-08-11
- Last updated
- 2024-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04999605. Inclusion in this directory is not an endorsement.